A new risk score can identify men and women under age 50 most likely to develop colorectal cancer, according to an international study led by researchers at NYU Langone Health and the Laura and Isaac Perlmutter Cancer Center.
Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity.
